The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics

• Status: Completed
• Trial end date: 2018-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of California, San Francisco
• Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Open Medicine Institute
• Treatments: Allopurinol

Criteria

Inclusion Criteria:

• self-identified as Asian/European ancestry

• generally healthy with approved lab values for CBC,HFP,RFP, and uric acid

• Subjects with the ABCG2 genotype, homozygous, heterozygous or homozygous for the major allele of rs2231142 will be recruited

Exclusion Criteria:

• vascular disease

• renal impairment

• medications/supplements that affect uric acid levels

• pregnant or lactating women

• prior history of allergic reaction to allopurinol or testing positive for HLA-B*5801 allele

• risk of urinary or gastric retention or narrow-angle glaucoma

• impaired hepatic function

• evidence of anemia

• evidence or diagnosis of congestive heart failure

• smokers

• subjects with a mutation other than rs2231142 in the ABCG2 genotype

• subjects taking hormonal contraceptives or other hormonal medications

• evidence of recreational drug use as determined by questionnaire